midodrine has been researched along with Chronic Kidney Failure in 21 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cool dialysate and midodrine have been used successfully to treat intradialytic hypotension (IDH) in the end-stage renal disease population." | 9.10 | Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. ( Abu-Alfa, AK; Hoeben, H; Mahnensmith, R; Perazella, MA, 2002) |
| " Midodrine is an α1 vasoconstrictor commonly used for the treatment of pulmonary arterial hypertension (PAH) and intradialytic hypotension." | 7.91 | Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis. ( Alobaidi, A; Bielnicka, P; Drambarean, B, 2019) |
| "Outpatient dialysis is possible and relieves the symptoms of congestive heart failure in patients with poor heart function, low blood pressure, and advanced age when midodrine is given immediately before and during the procedure." | 7.75 | Hemodialysis in hypotensive heart failure using midodrine. ( Bergman, SM, 2009) |
| "Midodrine appears to be an effective and safe treatment for HD patients with symptomatic IDH, and remains beneficial when used for an extended period of time." | 6.69 | Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. ( Brickel, HM; Cruz, DN; Mahnensmith, RL; Perazella, MA, 1998) |
| "Oral midodrine appears to be a safe and effective therapy for the treatment of hemodialysis hypotension." | 6.68 | Midodrine treatment for patients with hemodialysis hypotension. ( Caruso, FS; Flynn, JJ; McElligott, MA; Mitchell, MC, 1996) |
| "Midodrine treatment also significantly increased postdialysis systolic and diastolic blood pressures from baseline values of 90." | 6.68 | Midodrine for the treatment of intradialytic hypotension. ( Li, HP; Lim, PS; Lim, YT; Yang, CC; Yeh, CH, 1997) |
| "Midodrine is an alpha-agonist that causes peripheral vasoconstriction, resulting in increased blood pressure." | 6.44 | Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review. ( Haimov, M; Ross, MJ; Rubinstein, S, 2008) |
| "Other than scalp paresthesia in one patient, no adverse effects were noted." | 5.30 | Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997) |
| " The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function." | 5.29 | Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. ( Balfe, JW; Blowey, DL; Gajaria, MM; Gupta, I; Koren, G, 1996) |
| "Cool dialysate and midodrine have been used successfully to treat intradialytic hypotension (IDH) in the end-stage renal disease population." | 5.10 | Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. ( Abu-Alfa, AK; Hoeben, H; Mahnensmith, R; Perazella, MA, 2002) |
| " Midodrine is an α1 vasoconstrictor commonly used for the treatment of pulmonary arterial hypertension (PAH) and intradialytic hypotension." | 3.91 | Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis. ( Alobaidi, A; Bielnicka, P; Drambarean, B, 2019) |
| "Midodrine is prescribed to prevent symptomatic hypotension and decrease complications associated with hypotension during dialysis." | 3.83 | Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation. ( Alhamad, T; Axelrod, D; Brennan, DC; Brifkani, Z; Dharnidharka, VR; Lentine, KL; Schnitzler, MA; Segev, DL; Xiao, H, 2016) |
| "Outpatient dialysis is possible and relieves the symptoms of congestive heart failure in patients with poor heart function, low blood pressure, and advanced age when midodrine is given immediately before and during the procedure." | 3.75 | Hemodialysis in hypotensive heart failure using midodrine. ( Bergman, SM, 2009) |
| "Midodrine users were more commonly older (56." | 2.87 | Influence of pretransplant midodrine use on outcomes after kidney transplantation. ( Brennan, DC; Gharabagi, A; Hagopian, JC; Horwedel, TA; Pottebaum, AA, 2018) |
| "Midodrine appears to be an effective and safe treatment for HD patients with symptomatic IDH, and remains beneficial when used for an extended period of time." | 2.69 | Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. ( Brickel, HM; Cruz, DN; Mahnensmith, RL; Perazella, MA, 1998) |
| "Oral midodrine appears to be a safe and effective therapy for the treatment of hemodialysis hypotension." | 2.68 | Midodrine treatment for patients with hemodialysis hypotension. ( Caruso, FS; Flynn, JJ; McElligott, MA; Mitchell, MC, 1996) |
| "Midodrine treatment also significantly increased postdialysis systolic and diastolic blood pressures from baseline values of 90." | 2.68 | Midodrine for the treatment of intradialytic hypotension. ( Li, HP; Lim, PS; Lim, YT; Yang, CC; Yeh, CH, 1997) |
| "Midodrine is an alpha-agonist that causes peripheral vasoconstriction, resulting in increased blood pressure." | 2.44 | Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review. ( Haimov, M; Ross, MJ; Rubinstein, S, 2008) |
| "Other than scalp paresthesia in one patient, no adverse effects were noted." | 1.30 | Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? ( Cruz, DN; Mahnensmith, RL; Perazella, MA, 1997) |
| " The pharmacokinetic characteristics of the prodrug midodrine and the active metabolite de-glymidodrine in this patient with end-stage renal disease approximate those reported for patients with normal renal function." | 1.29 | Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. ( Balfe, JW; Blowey, DL; Gajaria, MM; Gupta, I; Koren, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pottebaum, AA | 1 |
| Hagopian, JC | 1 |
| Brennan, DC | 2 |
| Gharabagi, A | 1 |
| Horwedel, TA | 1 |
| Brunelli, SM | 1 |
| Cohen, DE | 1 |
| Marlowe, G | 1 |
| Van Wyck, D | 1 |
| Raina, R | 1 |
| Lam, S | 1 |
| Raheja, H | 1 |
| Krishnappa, V | 1 |
| Hothi, D | 1 |
| Davenport, A | 1 |
| Chand, D | 1 |
| Kapur, G | 1 |
| Schaefer, F | 1 |
| Sethi, SK | 1 |
| McCulloch, M | 1 |
| Bagga, A | 1 |
| Bunchman, T | 1 |
| Warady, BA | 1 |
| Drambarean, B | 1 |
| Bielnicka, P | 1 |
| Alobaidi, A | 1 |
| Tanabe, N | 1 |
| Takane, K | 1 |
| Yokoyama, K | 1 |
| Tanno, Y | 1 |
| Yamamoto, I | 1 |
| Ohkido, I | 1 |
| Yokoo, T | 1 |
| Alhamad, T | 1 |
| Brifkani, Z | 1 |
| Xiao, H | 1 |
| Schnitzler, MA | 1 |
| Dharnidharka, VR | 1 |
| Axelrod, D | 1 |
| Segev, DL | 1 |
| Lentine, KL | 1 |
| Rubinstein, S | 1 |
| Haimov, M | 1 |
| Ross, MJ | 1 |
| Bergman, SM | 1 |
| Hassinger, AB | 1 |
| Garimella, S | 1 |
| Blowey, DL | 1 |
| Balfe, JW | 1 |
| Gupta, I | 1 |
| Gajaria, MM | 1 |
| Koren, G | 1 |
| Flynn, JJ | 1 |
| Mitchell, MC | 1 |
| Caruso, FS | 1 |
| McElligott, MA | 1 |
| Lim, PS | 1 |
| Yang, CC | 1 |
| Li, HP | 1 |
| Lim, YT | 1 |
| Yeh, CH | 1 |
| Cruz, DN | 3 |
| Mahnensmith, RL | 3 |
| Perazella, MA | 6 |
| Brickel, HM | 2 |
| Han, SY | 1 |
| Kwon, YJ | 1 |
| Shin, JH | 1 |
| Pyo, HJ | 1 |
| Kim, AR | 1 |
| Montagnac, R | 2 |
| Clavel, P | 2 |
| Delhotal-Landes, B | 2 |
| Flouvat, B | 2 |
| Poulain, S | 2 |
| Schillinger, F | 1 |
| Alappan, R | 1 |
| Cruz, D | 1 |
| Abu-Alfa, AK | 2 |
| Mahnensmith, R | 2 |
| Schllinger, F | 1 |
| Hoeben, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hemodynamic Effects of Low vs. High Dialysate Temperature or Bicarbonate Concentration in Chronic Hemodialysis Patients[NCT05052151] | 16 participants (Actual) | Interventional | 2021-08-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for midodrine and Chronic Kidney Failure
| Article | Year |
|---|---|
Midodrine-induced vascular ischemia in a hemodialysis patient: a case report and literature review.
Topics: Adrenergic alpha-Agonists; Female; Humans; Ischemia; Kidney Failure, Chronic; Leg; Middle Aged; Mido | 2008 |
Pharmacologic options available to treat symptomatic intradialytic hypotension.
Topics: Adrenergic Agents; Autonomic Nervous System; Caffeine; Carnitine; Ephedrine; Fludrocortisone; Hemodi | 2001 |
7 trials available for midodrine and Chronic Kidney Failure
| Article | Year |
|---|---|
Influence of pretransplant midodrine use on outcomes after kidney transplantation.
Topics: Delayed Graft Function; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Graf | 2018 |
Midodrine treatment for patients with hemodialysis hypotension.
Topics: Adrenergic alpha-Agonists; Aged; Blood Pressure; Female; Humans; Hypotension; Kidney Failure, Chroni | 1996 |
Midodrine for the treatment of intradialytic hypotension.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Body Weight; Female; H | 1997 |
Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Topics: Adrenergic alpha-Agonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypotension; Kid | 1998 |
Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cold Temperature; Combined Modality Therapy; Cross-Over Stu | 1999 |
Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate.
Topics: Blood Pressure; Calcium; Female; Hemodialysis Solutions; Humans; Hypotension; Kidney Failure, Chroni | 2001 |
Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Blood Volume; Cardiac Output; Cold Temperatu | 2002 |
12 other studies available for midodrine and Chronic Kidney Failure
| Article | Year |
|---|---|
The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Follow-Up Studies; Hospitalization; Humans; Hypoten | 2018 |
Pediatric intradialytic hypotension: recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) Workgroup.
Topics: Age Factors; Blood Pressure; Blood Pressure Determination; Child; Consensus; Continuous Renal Replac | 2019 |
Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Epoprostenol; Humans; Hypotension; Kidney | 2019 |
Dialysate temperature adjustment as an effective treatment for baroreflex failure syndrome in hemodialysis patient.
Topics: Aged; Baroreflex; Carotid Sinus; Cold Temperature; Dialysis Solutions; Dizziness; Droxidopa; Enteral | 2014 |
Pretransplant Midodrine Use: A Newly Identified Risk Marker for Complications After Kidney Transplantation.
Topics: Adolescent; Adult; Aged; Blood Pressure; Delayed Graft Function; Female; Genetic Markers; Graft Surv | 2016 |
Hemodialysis in hypotensive heart failure using midodrine.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Female; Heart Failure; Humans; H | 2009 |
Refractory hypotension after bilateral nephrectomies in a Denys-Drash patient with phenylketonuria.
Topics: Adrenergic alpha-1 Receptor Agonists; Denys-Drash Syndrome; Female; Humans; Hypotension; Infant; Inf | 2013 |
Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension.
Topics: Adolescent; Adrenergic alpha-Agonists; Half-Life; Humans; Hypotension; Kidney Failure, Chronic; Male | 1996 |
Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients?
Topics: Administration, Oral; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Blood Pressure; Diastole; | 1997 |
Nonocclusive mesenteric ischemia in a patient on maintenance hemodialysis.
Topics: Aged; Colectomy; Colon; Female; Humans; Ischemia; Kidney Failure, Chronic; Mesentery; Midodrine; Ren | 2000 |
[Midodrine (Gutron) treatment of permanent arterial hypotension in a chronic hemodialysis patient].
Topics: Adrenergic alpha-Agonists; Chronic Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Hy | 2000 |
Use of midodrine (Gutron) to treat permanent hypotension in a chronic hemodialysis patient.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypotension; Kidney Failure, Chronic; Male | 2001 |